M Bonetti

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Patterns of treatment effects in subsets of patients in clinical trials
    Marco Bonetti
    Department of Biostatistics, Harvard School of Public Health and Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biostatistics 5:465-81. 2004
  2. ncbi request reprint A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data
    M Bonetti
    Department of Biostatistics, Harvard School of Public Health and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Stat Med 19:2595-609. 2000
  3. ncbi request reprint The interpoint distance distribution as a descriptor of point patterns, with an application to spatial disease clustering
    Marco Bonetti
    Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
    Stat Med 24:753-73. 2005
  4. ncbi request reprint Modelling menstrual status during and after adjuvant treatment for breast cancer
    Suzanne E Szwarc
    Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
    Stat Med 25:3534-47. 2006
  5. pmc Real time spatial cluster detection using interpoint distances among precise patient locations
    Karen L Olson
    Children s Hospital Informatics Program, Children s Hospital Boston, Boston, Massachusetts, USA
    BMC Med Inform Decis Mak 5:19. 2005
  6. ncbi request reprint Tailoring adjuvant treatments for the individual breast cancer patient
    R D Gelber
    IBCSG Statistical Center, Department of Biostatistical Science, Dana Farber Cancer Institute, 44 Binney Str, Boston, MA 02115, USA
    Breast 12:558-68. 2003
  7. ncbi request reprint Bivariate method for spatio-temporal syndromic surveillance
    Al Ozonoff
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
    MMWR Morb Mortal Wkly Rep 53:59-66. 2004
  8. pmc Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot
    Ann A Lazar
    Harvard School of Public Health, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:4539-44. 2010
  9. ncbi request reprint Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
    Monica Castiglione-Gertsch
    International Breast Cancer Study Group Coordinating Center and Inselspital, Bern, Switzerland
    J Natl Cancer Inst 95:1833-46. 2003
  10. ncbi request reprint A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness
    Bernard F Cole
    Department of Community and Family Medicine, Section of Biostatistics and Epidemiology, Dartmouth College Medical School, Lebanon, NH 03756, USA
    Stat Med 24:2317-34. 2005

Detail Information

Publications12

  1. ncbi request reprint Patterns of treatment effects in subsets of patients in clinical trials
    Marco Bonetti
    Department of Biostatistics, Harvard School of Public Health and Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Biostatistics 5:465-81. 2004
    ....
  2. ncbi request reprint A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data
    M Bonetti
    Department of Biostatistics, Harvard School of Public Health and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Stat Med 19:2595-609. 2000
    ..We apply STEPP to a breast cancer clinical trial data set to evaluate the treatment effect as a function of the oestrogen receptor content of the primary tumour...
  3. ncbi request reprint The interpoint distance distribution as a descriptor of point patterns, with an application to spatial disease clustering
    Marco Bonetti
    Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
    Stat Med 24:753-73. 2005
    ....
  4. ncbi request reprint Modelling menstrual status during and after adjuvant treatment for breast cancer
    Suzanne E Szwarc
    Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
    Stat Med 25:3534-47. 2006
    ..We discuss a parametric model for the time to amenorrhoea and for the time to the recovery of menses, also accounting for the presence of censoring and for the possibility that treatment causes an anticipation of natural menopause...
  5. pmc Real time spatial cluster detection using interpoint distances among precise patient locations
    Karen L Olson
    Children s Hospital Informatics Program, Children s Hospital Boston, Boston, Massachusetts, USA
    BMC Med Inform Decis Mak 5:19. 2005
    ....
  6. ncbi request reprint Tailoring adjuvant treatments for the individual breast cancer patient
    R D Gelber
    IBCSG Statistical Center, Department of Biostatistical Science, Dana Farber Cancer Institute, 44 Binney Str, Boston, MA 02115, USA
    Breast 12:558-68. 2003
    ..Unfortunately, information currently available is insufficient to properly tailor adjuvant treatments...
  7. ncbi request reprint Bivariate method for spatio-temporal syndromic surveillance
    Al Ozonoff
    Department of Biostatistics, Harvard School of Public Health, 655 Huntington Avenue, Boston, MA 02115, USA
    MMWR Morb Mortal Wkly Rep 53:59-66. 2004
    ..Statistical analysis of syndromic data has typically focused on univariate test statistics for spatial, temporal, or spatio-temporal surveillance. However, this approach does not take full advantage of the information available in the data...
  8. pmc Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot
    Ann A Lazar
    Harvard School of Public Health, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 28:4539-44. 2010
    ..STEPP analyses showed patients with higher Ki-67 values who were assigned to receive tamoxifen had the poorest prognosis and may benefit most from letrozole...
  9. ncbi request reprint Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial
    Monica Castiglione-Gertsch
    International Breast Cancer Study Group Coordinating Center and Inselspital, Bern, Switzerland
    J Natl Cancer Inst 95:1833-46. 2003
    ....
  10. ncbi request reprint A multistate Markov chain model for longitudinal, categorical quality-of-life data subject to non-ignorable missingness
    Bernard F Cole
    Department of Community and Family Medicine, Section of Biostatistics and Epidemiology, Dartmouth College Medical School, Lebanon, NH 03756, USA
    Stat Med 24:2317-34. 2005
    ..We apply the techniques to data from a breast cancer clinical trial in which QOL assessments were made longitudinally, and in which missing data frequently arose...
  11. ncbi request reprint Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Ca
    Günther Gruber
    Department of Radiation Oncology, and the Institute of Medical Oncology, Inselspital, Switzerland
    J Clin Oncol 23:7089-97. 2005
    ..We sought to determine retrospectively whether extracapsular spread (ECS) might identify a subgroup that could benefit from radiotherapy after mastectomy, especially patients with 1 to 3 positive lymph nodes (LN1-3+)...
  12. doi request reprint Another STEPP in the right direction
    Marco Bonetti
    J Clin Oncol 26:3813-4; author reply 3814-5. 2008